H. Lundbeck A/S/DKr HLUN B
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About H. Lundbeck A/S
H. Lundbeck A/S is a Danish pharmaceutical company specializing in the research, development, and marketing of products for the treatment of brain diseases. The company focuses on areas such as depression, schizophrenia, Alzheimer's disease, and Parkinson's disease. Founded in 1915, Lundbeck is headquartered in Valby, Denmark, and has a significant global presence with facilities across Europe, North America, and Asia. Lundbeck's strategic positioning is underscored by its dedicated emphasis on central nervous system disorders, supported by a robust pipeline of research and development projects. The company places a strong emphasis on scientific and clinical excellence, aiming to deliver innovative therapies to improve patient outcomes.
- Ticker
- DKr HLUN B
- Sector
- Health
- Primary listing
- CSE
- Employees
- 5,000
- Headquarters
- Valby, Denmark
- Website
- www.lundbeck.com
H. Lundbeck A/S Metrics
BasicAdvanced
kr 53B
13.78
kr 3.97
0.26
kr 1.15
2.10%
Price and volume
Market cap
kr 53B
Beta
0.26
52-week high
kr 55.05
52-week low
kr 35.30
Average daily volume
835K
Dividend rate
kr 1.15
Financial strength
Current ratio
1.367
Quick ratio
0.899
Long term debt to equity
0.348
Total debt to equity
0.351
Dividend payout ratio (TTM)
29.00%
Interest coverage (TTM)
405.50%
Profitability
EBITDA (TTM)
8,270
Gross margin (TTM)
82.06%
Net profit margin (TTM)
15.16%
Operating margin (TTM)
24.99%
Effective tax rate (TTM)
27.65%
Revenue per employee (TTM)
kr 5,190,000
Management effectiveness
Return on assets (TTM)
7.76%
Return on equity (TTM)
15.41%
Valuation
Price to earnings (TTM)
13.777
Price to revenue (TTM)
2.088
Price to book
1.98
Price to tangible book (TTM)
-5.8
Price to free cash flow (TTM)
10.515
Free cash flow yield (TTM)
9.51%
Free cash flow per share (TTM)
5.198
Dividend yield (TTM)
2.10%
Forward dividend yield
2.10%
Growth
Revenue change (TTM)
10.37%
Earnings per share change (TTM)
14.67%
3-year revenue growth (CAGR)
10.23%
10-year revenue growth (CAGR)
5.69%
3-year earnings per share growth (CAGR)
16.68%
10-year earnings per share growth (CAGR)
11.72%
3-year dividend per share growth (CAGR)
25.63%
Bulls say / Bears say
H1 revenue rose 16% at constant exchange rates, or 13% excluding a one-off inventory build, led by Vyepti growth of 46% and Rexulti growth of 17%. That shows strong demand for Lundbeck’s main growth brands. (H. Lundbeck A/S)
Lundbeck raised its 2026 targets to 7–9% revenue growth and 8–14% adjusted EBITDA growth, then maintained them after its strong first half. This gives near-term growth expectations a firmer footing. (H. Lundbeck A/S)
Bocunebart reported positive Phase IIb results in migraine prevention, while bexicaserin and amlenetug advanced through pivotal Phase III trials. These programmes offer potential future growth catalysts beyond today’s established brands. (H. Lundbeck A/S, PR Newswire)
The first-half figures benefited from a one-off DKK 470 million inventory build. Excluding it, adjusted EBITDA growth was 10% rather than 19%, and faster research spending contributed to weaker growth in the second quarter. (H. Lundbeck A/S)
Rexulti accounts for roughly a quarter of revenue and faces competition from Auvelity, a planned US Medicare price cut in 2028 and patent expiry in 2029. Generic entrants are also expected to pressure Abilify Maintena in Canada and Australia. (Investing.com, Fierce Pharma)
A Phase Ib analysis of Lu AG22515 did not confirm the expected clinical effect in thyroid eye disease, so Lundbeck stopped development in that indication. This highlights the risk that clinical programmes may fail to deliver the pipeline growth investors are counting on. (ChosunBiz)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
Upcoming events
No upcoming events
Funds containing H. Lundbeck A/S
Fund name | Fund size | DKr HLUN B weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.21% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.21% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.21% |
iShares Ageing Population$AGED | $953M | 0.19% |
iShares Ageing Population€AGED | $903M | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.